Alternative Carer Respite: A Study on Its Effectiveness and Potential Mechanism
Launched by THE UNIVERSITY OF HONG KONG · May 26, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called "Alternative Carer Respite," is looking into how effective a special support program is for older adults in Hong Kong who either have no children or have limited contact with their children. The goal is to help these older adults, and in turn, help their caregivers by reducing stress and improving their overall well-being. The study will evaluate caregivers before the program starts, right after it ends, and three months later to see how their physical health, mental health, social interactions, and satisfaction levels change.
To participate, caregivers or the older adults they care for need to be at least 60 years old and meet certain criteria, such as having no children or having very little contact with their children. Participants will be invited to join voluntarily and will be assessed on various aspects of their health and happiness throughout the study. This trial is currently recruiting participants and aims to provide valuable insights into the needs of caregivers and their loved ones in similar situations.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Either the CR or CG is aged ≥60
- • Reported having (a) no children; OR (b) no children in Hong Kong; OR (c) having children in Hong Kong but with limited contact (i.e., fewer than once per month in any forms)
- • Voluntary participation.
- Exclusion Criteria:
- • Unable to communicate in neither Cantonese, English nor Mandarin
About The University Of Hong Kong
The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Patients applied
Trial Officials
Vivian Weiqun Lou, PhD
Principal Investigator
Sau Po Centre on Ageing, University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported